eISSN: 1733-7607
ISSN: 1733-4101
Leczenie Ran
Current issue Archive About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

2/2021
vol. 18
 
Share:
Share:
more
 
 
abstract:
Review paper

Cathelicidin – what’s new in the treatment of chronic wounds?

Tomasz Grzela
1, 2

1.
Klinika Flebologii w Warszawie
2.
Centrum Biostruktury, Warszawski Uniwersytet Medyczny
LECZENIE RAN 2021; 18 (2): 45–50
Online publish date: 2021/06/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Chronic wound treatment is a big clinical, logistic, and economic challenge. Therefore, the search for new solutions to improve treatment effectiveness is crucial. Optimal conditions for wound healing may be achieved by a causative approach and proper local treatment. However, sometimes even the standard of care procedures and the use of advanced modern dressings cannot guarantee success. This may be due to the presence of a microbial biofilm that sustains chronic inflammation of the wound bed. The main difficulties in biofilm eradication result not only from the fact that bacteria in that form are more resistant to the majority of antibiotics, but also because they are protected from contact with immunocompetent cells. Fortunately, our defence system exploits a curious component of innate immunity: small antimicrobial peptides. The uniqueness of these peptides is due to the fact that, apart from their main antimicrobial action, some of them may also reveal numerous other beneficial properties, which appear to be useful in chronic wound treatment. The aim of this work is to present to the readers one of these unique peptides: cathelicidin.
keywords:

cathelicidin, LL-37, antimicrobial peptides, AMP, chronic wounds

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe